Background Triple negative breast cancer (TNBC) in humans is defined by the absence of oestrogen receptor (ER), progesterone receptor (PR) and HER2 overexpression. Mammalian target of rapamycin (mTOR) is overexpressed in TNBC and it represents a potential target for the treatment of this aggressive tumour. Feline mammary carcinoma (FMC) is considered to be a model for hormone-independent human breast cancer. This study investigated mTOR and p-mTOR expression in FMC in relation to triple negative (TN) phenotype. Results The expression of mTOR, p-mTOR, ERα, PR and HER2 was evaluated in 58 FMCs by immunohistochemistry and in six FMC cell lines by Western blot analysis. 53.5% of FMC analyzed were ER, PR, HER2 negative (TN-FMC) while 56.9% and 55.2% of cases expressed mTOR and p-mTOR respectively. In this study we found that m-TOR and p-mTOR were more frequently detected in TN-FMC and in HER2 negative samples. Conclusions In this study, we demonstrate that there is also a FMC subset defined as TN FMC, which is characterised by a statistically significant association with m-TOR and p-mTOR expression as demonstrated in human breast cancer.

Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas

MANISCALCO, LORELLA;IUSSICH, Selina;DENINA, MARCO;SANCHEZ CESPEDES, Raquel;GATTINO, FRANCESCA;BIOLATTI, Bartolomeo;DI RENZO, Maria Flavia;DE MARIA, RAFFAELLA
2013

Abstract

Background Triple negative breast cancer (TNBC) in humans is defined by the absence of oestrogen receptor (ER), progesterone receptor (PR) and HER2 overexpression. Mammalian target of rapamycin (mTOR) is overexpressed in TNBC and it represents a potential target for the treatment of this aggressive tumour. Feline mammary carcinoma (FMC) is considered to be a model for hormone-independent human breast cancer. This study investigated mTOR and p-mTOR expression in FMC in relation to triple negative (TN) phenotype. Results The expression of mTOR, p-mTOR, ERα, PR and HER2 was evaluated in 58 FMCs by immunohistochemistry and in six FMC cell lines by Western blot analysis. 53.5% of FMC analyzed were ER, PR, HER2 negative (TN-FMC) while 56.9% and 55.2% of cases expressed mTOR and p-mTOR respectively. In this study we found that m-TOR and p-mTOR were more frequently detected in TN-FMC and in HER2 negative samples. Conclusions In this study, we demonstrate that there is also a FMC subset defined as TN FMC, which is characterised by a statistically significant association with m-TOR and p-mTOR expression as demonstrated in human breast cancer.
9
80
1
8
Maniscalco, L; Millán, Y; Iussich, S; Denina, M; Sánchez-Céspedes, R; Gattino, F; Biolatti, B; Sasaki, N; Nakagawa, T; Di Renzo, Mf; de Las Mulas, Jm; De Maria, R.
File in questo prodotto:
File Dimensione Formato  
DeMaria_mTOR_BMC_2013.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 495.18 kB
Formato Adobe PDF
495.18 kB Adobe PDF Visualizza/Apri
DeMaria_mTOR_BMC_2013_4aperto.pdf

Accesso aperto

Descrizione: articolo principale
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 555.27 kB
Formato Adobe PDF
555.27 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/127713
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 12
social impact